Today’s New York Times has published another of its fantastic articles about cancer and coping with cancer. Today’s article, written by Jane Brody, discusses chemo brain. Until a short time ago, many doctors denied that it even existed, but today it is pretty much accepted as being real. One is said to suffer from chemo [...]
Many doctors believe that increased levels of C-reactive protein (CRP) is associated with adverse outcomes in men with castration-resistant prostate cancer (CRPC) treated with docetaxel. C-reactive protein is a protein found in the blood, the levels of which rise in response to inflammation in any part of the body. Traditionally measuring levels of c-reactive protein [...]
Second of Three Pivotal Phase Three Bone Metastases Trials Meets Primary Endpoint Denosumab Delayed Time to Skeletal Related Events Amgen (NASDAQ: AMGN) has announced positive results from a Phase III head-to-head trial evaluating denosumab administered subcutaneously, versus Zometa (zoledronic acid) administered as an intravenous (IV) infusion. Currently Zometa is the FDA approved treatment for bone [...]
The authors of a recent study from the Duke Prostate Center and Division of Urology, Department of Surgery, Duke University Medical Center, Durham, N.C. and the Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan reviewed the current salvage methods for treating recurrent local recurrent prostate cancer after primary radiotherapy (RT). They used a [...]
One of the first treatments used when diagnosed with advanced or recurrent prostate cancer is hormone therapy. Hormone therapy (androgen blockade) is a systematic treatment, or it treats the cancer through the entire body. Prostate cancer that is believed to be in the gland is treated with a localized, focused treatment of the actual gland [...]